Bright Minds Biosciences, Inc. (DRUG.CX)
73.26
+2.37
(+3.34%)
CAD |
CNSX |
Oct 23, 16:00
Bright Minds Biosciences Enterprise Value : 414.88M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 414.88M |
| October 22, 2026 | 391.50M |
| October 21, 2026 | 457.20M |
| October 20, 2026 | 473.97M |
| October 19, 2026 | 427.61M |
| October 16, 2026 | 412.61M |
| October 15, 2026 | 447.24M |
| October 14, 2026 | 392.59M |
| October 13, 2026 | 428.79M |
| October 09, 2026 | 452.76M |
| October 08, 2026 | 417.45M |
| October 07, 2026 | 417.64M |
| October 06, 2026 | 374.83M |
| October 05, 2026 | 407.68M |
| October 02, 2026 | 388.54M |
| October 01, 2026 | 392.00M |
| September 30, 2026 | 385.98M |
| September 29, 2026 | 395.25M |
| September 28, 2026 | 416.16M |
| September 25, 2026 | 421.39M |
| September 24, 2026 | 464.30M |
| September 23, 2026 | 496.56M |
| September 22, 2026 | 547.16M |
| September 21, 2026 | 524.27M |
| September 18, 2026 | 515.99M |
| Date | Value |
|---|---|
| September 17, 2026 | 535.62M |
| September 16, 2026 | 504.25M |
| September 15, 2026 | 518.16M |
| September 14, 2026 | 570.73M |
| September 11, 2026 | 564.22M |
| September 10, 2026 | 567.28M |
| September 09, 2026 | 580.10M |
| September 08, 2026 | 596.87M |
| September 04, 2026 | 600.62M |
| September 03, 2026 | 622.22M |
| September 02, 2026 | 669.28M |
| September 01, 2026 | 655.96M |
| August 31, 2026 | 663.85M |
| August 28, 2026 | 694.53M |
| August 27, 2026 | 707.45M |
| August 26, 2026 | 748.09M |
| August 25, 2026 | 775.02M |
| August 24, 2026 | 755.78M |
| August 21, 2026 | 759.14M |
| August 20, 2026 | 771.47M |
| August 19, 2026 | 816.65M |
| August 18, 2026 | 823.55M |
| August 17, 2026 | 758.94M |
| August 14, 2026 | 751.05M |
| August 13, 2026 | 774.53M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Fennec Pharmaceuticals, Inc. | 458.58M |
| Microbix Biosystems, Inc. | 43.39M |
| Helix BioPharma Corp. | 60.15M |
| Sernova Biotherapeutics, Inc. | 56.09M |
| Hemostemix, Inc. | 14.64M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -2.398M |
| Total Expenses (Quarterly) | 2.398M |
| EPS Diluted (Quarterly) | -0.244 |
| Earnings Yield | -3.93% |
| Normalized Earnings Yield | -3.930 |